PDGFRB-associated chronic eosinophilic leukemia

*PDGFRB*-associated chronic eosinophilic leukemia is a type of cancer of blood-forming cells. It is characterized by an elevated number of white blood cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in *PDGFRB*-associated chronic eosinophilic leukemia. Some people with this condition have an increased number of other types of white blood cells, such as neutrophils or mast cells, in addition to eosinophils. People with this condition can have an enlarged spleen (splenomegaly) or enlarged liver (hepatomegaly). Some affected individuals develop skin rashes, likely as a result of an abnormal immune response due to the increased number of eosinophils.

**Frequency**

The exact prevalence of *PDGFRB*-associated chronic eosinophilic leukemia is unknown. For unknown reasons, males are up to nine times more likely than females to develop *PDGFRB*-associated chronic eosinophilic leukemia.

**Causes**

*PDGFRB*-associated chronic eosinophilic leukemia is caused by genetic rearrangements that join part of the *PDGFRB* gene with part of another gene. At least 20 genes have been found that fuse with the *PDGFRB* gene to cause *PDGFRB*-associated chronic eosinophilic leukemia. The most common genetic abnormality in this condition results from a rearrangement (translocation) of genetic material that brings part of the *PDGFRB* gene on chromosome 5 together with part of the *ETV6* gene on chromosome 12, creating the *ETV6-PDGFRB* fusion gene.

The *PDGFRB* gene provides instructions for making a protein that plays a role in turning on (activating) signaling pathways that control many cell processes, including cell growth and division (proliferation). The *ETV6* gene provides instructions for making a protein that turns off (represses) gene activity. This protein is important in development before birth and in regulating blood cell formation. The protein produced from the *ETV6-PDGFRB* fusion gene, called ETV6/PDGFRβ, functions differently than the proteins normally produced from the individual genes. Like the normal PDGFRβ protein, the ETV6/PDGFRβ fusion protein turns on signaling pathways. However, the fusion protein does not need to be turned on to be active, so the signaling pathways are constantly turned on (constitutively activated). The fusion protein is unable to repress gene activity regulated by the normal ETV6 protein, so gene activity is increased. The constitutively active signaling pathways and abnormal gene activity increase the proliferation and survival of cells.
When the *ETV6-PDGFRB* fusion gene mutation occurs in cells that develop into blood cells, the growth of eosinophils (and occasionally other blood cells, such as neutrophils and mast cells) is poorly controlled, leading to *PDGFRB*-associated chronic eosinophilic leukemia. It is unclear why eosinophils are preferentially affected by this genetic change.

**Inheritance Pattern**

*PDGFRB*-associated chronic eosinophilic leukemia is not inherited and occurs in people with no history of the condition in their families. Chromosomal rearrangements that lead to a *PDGFRB* fusion gene are somatic mutations, which are mutations acquired during a person's lifetime and present only in certain cells. The somatic mutation occurs initially in a single cell, which continues to grow and divide, producing a group of cells with the same mutation (a clonal population).

**Other Names for This Condition**

- atypical Philadelphia-negative chronic myeloid leukemia
- chronic myelomonocytic leukemia
- chronic myeloproliferative disorder with eosinophilia
- clonal eosinophilia with chronic myeloproliferative disorder
- primary eosinophilia with chronic myeloproliferative disorder

**Diagnosis & Management**

**Genetic Testing Information**

- What is genetic testing? /primer/testing/genetictesting

**Research Studies from ClinicalTrials.gov**

- ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=%22PDGFRB-associated+chronic+eosinophilic+leukemia%22+OR+%22hypereosinophilic+syndrome%22
Other Diagnosis and Management Resources

- Cancer.Net: Leukemia--Eosinophilic: Treatment
  https://www.cancer.net/cancer-types/leukemia-eosinophilic/treatment-options?sectionTitle=Treatment

- MedlinePlus Encyclopedia: Eosinophil Count--Absolute
  https://medlineplus.gov/ency/article/003649.htm

- Seattle Cancer Care Alliance: Hypereosinophilia
  https://www.seattlecca.org/diseases/blood-disorders/eosinophilic-disorders

Additional Information & Resources

Health Information from MedlinePlus

- Encyclopedia: Eosinophil Count--Absolute
  https://medlineplus.gov/ency/article/003649.htm

- Health Topic: Eosinophilic Disorders
  https://medlineplus.gov/eosinophilicdisorders.html

Genetic and Rare Diseases Information Center

- PDGFRB-associated chronic eosinophilic leukemia

Additional NIH Resources

- National Cancer Institute: Chronic Eosinophilic Leukemia
  https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq#section/_258

Educational Resources

- Cancer.Net: Leukemia--Eosinophilic
  https://www.cancer.net/cancer-types/leukemia-eosinophilic?sectionTitle=Overview

- Cincinnati Children's Hospital: Cincinnati Center for Eosinophilic Disorders
  https://www.cincinnatichildrens.org/service/c/eosinophilic-disorders/conditions/eosinophil

- MalaCards: pdgfrb-associated chronic eosinophilic leukemia
  https://www.malacards.org/card/pdgfrb_associated_chronic_eosinophilic_leukemia

- Merck Manual for Health Care Professionals: Eosinophilia
  https://www.merckmanuals.com/professional/hematology-and-oncology/eosinophilic-disorders/eosinophilia

- Orphanet: Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=168950
Patient Support and Advocacy Resources

- American Cancer Society  
  https://www.cancer.org/
- American Partnership for Eosinophilic Disorders  
  https://apfed.org/
- Cancer Support Community  
  https://www.cancersupportcommunity.org/
- The Leukemia & Lymphoma Society  
  https://www.lls.org/

Scientific Articles on PubMed

- PubMed  
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28pdgfrb%5BTIAB%5D%29+AND+%28eosinophilia%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12181402
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22587685
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22356850  
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307482/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18566537
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19758395
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20071982
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22926771

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22162288

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22449622

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22373549

Reprinted from Genetics Home Reference:

Reviewed: February 2013
Published: November 12, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services